Kim SS - Search Results

1

Correction: Proteogenomic characterization of molecular and cellular targets for treatment‑resistant subtypes in locally advanced cervical cancers.

Hyeon DY, Nam D, Shin HJ, Jeong J, Jung E, Cho SY, Shin DH, Ku JL, Baek HJ, Yoo CW, Hong EK, Lim MC, Lee SJ, Bae YK, Kim JK, Bae J, Choi W, Kim SJ, Back S, Kang C, Madar IH, Kim H, Kim S, Kim DK, Kang J, Park GW, Park KS, Shin Y, Kim SS, Jung K, Hwang D, Lee SW, Kim JY. Hyeon DY, et al. Among authors: kim jy, kim ss, kim jk, kim h, kim s, kim sj, kim dk. Mol Cancer. 2025 Jun 11;24(1):174. doi: 10.1186/s12943-025-02373-z. Mol Cancer. 2025. PMID: 40500697 Free PMC article. No abstract available.

2

Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis.

Baek HJ, Lim SC, Kitisin K, Jogunoori W, Tang Y, Marshall MB, Mishra B, Kim TH, Cho KH, Kim SS, Mishra L. Baek HJ, et al. Among authors: kim ss, kim th. Hepatology. 2008 Oct;48(4):1128-37. doi: 10.1002/hep.22460. Hepatology. 2008. PMID: 18704924 Free PMC article.

3

ATM is required for rapid degradation of cyclin D1 in response to gamma-irradiation.

Choo DW, Baek HJ, Motoyama N, Cho KH, Kim HS, Kim SS. Choo DW, et al. Among authors: kim ss, kim hs. Biochem Biophys Res Commun. 2009 Jan 23;378(4):847-50. doi: 10.1016/j.bbrc.2008.11.132. Epub 2008 Dec 9. Biochem Biophys Res Commun. 2009. PMID: 19071090

4

Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumors.

Choi EK, Lim JA, Kim JK, Jang MS, Kim SE, Baek HJ, Park EJ, Kim TH, Deng CX, Wang RH, Kim SS. Choi EK, et al. Among authors: kim ss, kim jk, kim se, kim th. Exp Mol Med. 2018 Oct 16;50(10):1-16. doi: 10.1038/s12276-018-0169-z. Exp Mol Med. 2018. PMID: 30327455 Free PMC article.

5

Loss of BRCA1 Spontaneously Induces the Tumorigenesis in Lacrimal Gland.

Kim SE, Baek HJ, Park EJ, Lim SC, Kim SS. Kim SE, et al. Among authors: kim ss. Anal Cell Pathol (Amst). 2018 Dec 17;2018:8120579. doi: 10.1155/2018/8120579. eCollection 2018. Anal Cell Pathol (Amst). 2018. PMID: 30652068 Free PMC article.

6

Dose Profile Modulation of Proton Minibeam for Clinical Application.

Kim M, Hwang UJ, Park K, Kim D, Kim HS, Choi SH, Jeong JH, Shin D, Lee SB, Kim JY, Kim TH, Baek HJ, Kim H, Kim K, Kim SS, Lim YK. Kim M, et al. Among authors: kim jy, kim ss, kim h, kim th, kim d, kim hs, kim k. Cancers (Basel). 2022 Jun 11;14(12):2888. doi: 10.3390/cancers14122888. Cancers (Basel). 2022. PMID: 35740553 Free PMC article.

7

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.

Shin DH, Jo JY, Choi M, Kim KH, Bae YK, Kim SS. Shin DH, et al. Among authors: kim ss, kim kh. Exp Mol Med. 2023 Oct;55(10):2220-2237. doi: 10.1038/s12276-023-01091-0. Epub 2023 Oct 2. Exp Mol Med. 2023. PMID: 37779142 Free PMC article.

8

Inhibition of mTOR attenuates the initiation and progression of BRCA1-associated mammary tumors.

Baek HJ, Han GH, Cho EJ, Xu J, Ki MK, Park EJ, Kim TH, Shin DH, Cheong H, Deng CX, Lim SC, Hwang CI, Hwang D, Kim SS. Baek HJ, et al. Among authors: kim ss, kim th. Cancer Commun (Lond). 2025 Apr;45(4):486-490. doi: 10.1002/cac2.12663. Epub 2025 Jan 18. Cancer Commun (Lond). 2025. PMID: 39826130 Free PMC article. No abstract available.

9

Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers.

Hyeon DY, Nam D, Shin HJ, Jeong J, Jung E, Cho SY, Shin DH, Ku JL, Baek HJ, Yoo CW, Hong EK, Lim MC, Lee SJ, Bae YK, Kim JK, Bae J, Choi W, Kim SJ, Back S, Kang C, Madar IH, Kim H, Kim S, Kim DK, Kang J, Park GW, Park KS, Shin Y, Kim SS, Jung K, Hwang D, Lee SW, Kim JY. Hyeon DY, et al. Among authors: kim jy, kim ss, kim jk, kim h, kim s, kim sj, kim dk. Mol Cancer. 2025 Mar 14;24(1):77. doi: 10.1186/s12943-025-02256-3. Mol Cancer. 2025. PMID: 40087745 Free PMC article.

10

Targeting TGF-β-Smad2/3-JNK1-mediated SIRT1 activity overcomes the chemoresistance of KRAS mutation lung cancer.

Shin DH, Choi M, Han C, Kim SS. Shin DH, et al. Among authors: kim ss. Exp Mol Med. 2025 Sep;57(9):2022-2039. doi: 10.1038/s12276-025-01536-8. Epub 2025 Sep 12. Exp Mol Med. 2025. PMID: 40935852 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,609 results

Search Page

Filters